[{"id":"f98e10ef-ecf5-4a3d-b5b3-240b7e0bd849","acronym":"","url":"https://clinicaltrials.gov/study/NCT06439836","created_at":"2024-06-08T04:14:47.148Z","updated_at":"2025-02-25T14:11:06.436Z","phase":"Phase 1","brief_title":"Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy","source_id_and_acronym":"NCT06439836","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD68 • CRP","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD68 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • emavusertib (CA-4948)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 02/21/2025","start_date":" 02/21/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-18"},{"id":"4346ba5f-67b8-4706-8e12-549591ad58c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06696768","created_at":"2025-02-25T20:15:51.863Z","updated_at":"2025-02-25T20:15:51.863Z","phase":"Phase 1","brief_title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06696768","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • IL6 • CCL2 • CXCL1 • IRAK4","pipe":"","alterations":" ","tags":["IFNG • IL6 • CCL2 • CXCL1 • IRAK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-01-16"},{"id":"15953f0f-132c-44a4-9f39-8d36bdd31ec9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04278768","created_at":"2021-05-11T14:53:15.390Z","updated_at":"2024-07-02T16:35:15.352Z","phase":"Phase 1/2","brief_title":"Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS","source_id_and_acronym":"NCT04278768","lead_sponsor":"Curis, Inc.","biomarkers":" FLT3 • SF3B1 • U2AF1","pipe":" | ","alterations":" FLT3 mutation • SF3B1 mutation • U2AF1 mutation","tags":["FLT3 • SF3B1 • U2AF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • SF3B1 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)"],"overall_status":"Recruiting","enrollment":" Enrollment 366","initiation":"Initiation: 07/06/2020","start_date":" 07/06/2020","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-03-11"},{"id":"442996ad-1b63-4038-bf78-7db12fc6ab36","acronym":"","url":"https://clinicaltrials.gov/study/NCT05187182","created_at":"2022-01-11T15:56:11.756Z","updated_at":"2024-07-02T16:35:27.278Z","phase":"Phase 1","brief_title":"CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","source_id_and_acronym":"NCT05187182","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • emavusertib (CA-4948)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2023-12-04"}]